AGP Picks
View all

Healthy Living Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.

Press releases published on June 29, 2026

Hope Spring New Borehole Brings Safe Drinking Water to a Community in Osun State.
Stroke Diagnostics and Therapeutics Market to Reach US$ 74.1 Billion by 2033 at a CAGR of 7.8%
New Book Names 'Organisational Gravity,' the Hidden Force That Pulls Companies Away From Their Own Customers
Alyssum Therapeutics announces Nature Nanotechnology publication on first B cell-activating drug to treat solid tumors
Ad Scientiam Unveils Positive Interim 1-Year Longitudinal Results for MSCopilot® at EAN 2026
How a Single Genetic Change Derails Enamel Formation in Developing Teeth
Naqi Logix Appoints Dino Mariutti to the Board of Directors to Drive Strategic Growth
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Low grip strength should not be used as an independent predictor of prostate cancer in older men
Guangdong Baoshan Trading: Multi-Grade PVC Vinyl Supply Chain and Quality Control for Global Procurement
Twentyeight Health partners with Clue to expand access to affordable birth control nationwide
PrivacyScrubber 1.5.2 Adds Offline OCR & Omnibox Quick-Scrub for AI Workflows
PetVivo Reports Financial and Operational Results for Fiscal 2026
Zoumalan, MD FACS Inc. Announces Its Natural Looking Blepharoplasty® Approach as Demand Grows for Natural Eyelid Surgery Results
Tilray Brands Strengthens Global Medical Cannabis Platform and Canadian Patient Access Through HelloMD Acquisition
FISHER HOUSE FOUNDATION RECEIVES “FOUR STARS” FOR 22nd YEAR FROM CHARITY NAVIGATOR, A+ FROM CHARITY WATCH
Rayca Precision and Data Powered Therapeutics Partner to Advance AI-Designed Nanobody Cancer Therapeutics
Publication relating to transparency notifications
Publication relative à des notifications de transparence
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.